Unknown

Dataset Information

0

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.


ABSTRACT: PURPOSE:Therapeutic regimens for adult T-cell leukemia/lymphoma (ATL) are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard to response, duration of response, progression-free survival, and overall survival in patients with human T-cell lymphotropic virus-1 (HTLV-1)-associated ATL. EXPERIMENTAL DESIGN:Twenty-nine patients with chronic, acute, and lymphomatous types of ATL were enrolled in a single-institution, nonrandomized, open-label phase II trial wherein patients received intravenous alemtuzumab 30 mg three times weekly for a maximum of 12 weeks. RESULTS:Twenty-nine patients were evaluable for response and toxicity. The overall objective response was 15 of 29 patients [95% confidence interval (CI), 32.5%-70.6%]. The 15 patients who responded manifested a median time to response of 1.1 months. Median response duration was 1.4 months for the whole group and 14.5 months among responders. Median progression-free survival was 2.0 months. Median overall survival was 5.9 months. The most common adverse events were 2 with vasovagal episodes (7%) and 3 with hypotensive episodes (10%), leukopenia (41%) grade 3 and (17%) grade 4, lymphocytopenia (59%) grade 3, neutropenia (31%) grade 3, anemia (24%), and thrombocytopenia (10%). All patients developed cytomegalovirus antigenemia (CMV). Three were symptomatic and all responded to antiviral therapy. Grade 3 or 4 infections were reported in 4 (14%) of patients. CONCLUSIONS:Alemtuzumab induced responses in patients with acute HTLV-1-associated ATL with acceptable toxicity, but with short duration of responses. These studies support inclusion of alemtuzumab in novel multidrug therapies for ATL. Clin Cancer Res; 23(1); 35-42. ©2016 AACR.

SUBMITTER: Sharma K 

PROVIDER: S-EPMC5215752 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.

Sharma Kamal K   Janik John E JE   O'Mahony Deirdre D   Stewart Donn D   Pittaluga Stefania S   Stetler-Stevenson Maryalice M   Jaffe Elaine S ES   Raffeld Mark M   Fleisher Thomas A TA   Lee Cathryn C CC   Steinberg Seth M SM   Waldmann Thomas A TA   Morris John C JC  

Clinical cancer research : an official journal of the American Association for Cancer Research 20160802 1


<h4>Purpose</h4>Therapeutic regimens for adult T-cell leukemia/lymphoma (ATL) are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard to response, duration of response, progression-free survival, and overall survival in patients with human T-cell lymphotropic virus-1 (HTLV-1)-associated ATL.<h4>Experimental design</h4>Twenty-nine patients with chronic, acute, and lymphomatous ty  ...[more]

Similar Datasets

| S-EPMC7989087 | biostudies-literature
| S-EPMC4582992 | biostudies-literature
| S-EPMC7260950 | biostudies-literature
| S-EPMC8078141 | biostudies-literature
| S-EPMC3131883 | biostudies-literature
| S-EPMC8670839 | biostudies-literature
| S-EPMC10823268 | biostudies-literature
| S-EPMC5623751 | biostudies-literature
| S-EPMC2701868 | biostudies-literature
| S-EPMC7935801 | biostudies-literature